Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 11/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18712023 | 0.88 | ROCK2 (0.42) | ROCK1ROCK2RPS6KB1TRPA1MAPK14 | |
| SCHEMBL15639401 | 0.86 | ROCK1 (0.53) | ROCK1ROCK2AURKAERBB2CSF1R | |
| SCHEMBL15638875 | 0.86 | ROCK1 (0.43) | ROCK1ROCK2AURKAERBB2CSF1R | |
| SCHEMBL15638690 | 0.79 | MAPK14 (0.47) | ROCK1ROCK2RPS6KB1TRPA1TGFBR1 | |
| SCHEMBL16473226 | 0.78 | TRPA1 (0.54) | ROCK2AURKBTRPA1TGFBR1MAPK14 | |
| SCHEMBL15639986 | 0.75 | FGFR1 (0.51) | ROCK2AURKBTRPA1TGFBR1MAPK14 | |
| SCHEMBL30117579 | 0.75 | FGFR1 (0.51) | ROCK2AURKBTRPA1TGFBR1MAPK14 | |
| SCHEMBL12059777 | 0.75 | ROCK2 (0.70) | ROCK1ROCK2AURKARPS6KB1AKT1 | |
| SCHEMBL15639962 | 0.73 | NPY1R (0.43) | ROCK1ROCK2RPS6KB1AKT1STK3 | |
| SCHEMBL15638460 | 0.73 | ROCK2 (0.48) | ROCK1ROCK2RPS6KB1AKT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | ROCK1 471/4885ROCK2 416/4885AURKA 365/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | ROCK1 229/4885ROCK2 500/4885AURKA 3992/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | ROCK1 306/4885ROCK2 202/4885AURKA 312/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | ROCK1 424/4885ROCK2 267/4885AURKA 330/4885 |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR1, TGFBR2, ACVR1 | ROCK1 471/4885ROCK2 416/4885AURKA 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.